Oramed Pharmaceuticals Logo
US68403P2039
A1CTNU
ORMP.TA

Oramed Pharmaceuticals

Prognoza

Kupuj
  6
Trzymaj
  2
Sprzedaj
  0

Dyskusje w społeczności

Nie ma jeszcze dyskusji o tym aktywie.

Rozpocznij dyskusję

  • Lifeward shareholders approve partnership with Oramed and potential capital injection

    Lifeward has approved the issuance of common shares as part of a strategic partnership with Oramed, potentially giving the company access to up to about $47 million from Oramed and an additional investor. The financing includes equity, convertible bonds, milestone payments and warrants. Oramed will manage and fund the clinical development program for the POD technology, which aims to enable oral delivery of biopharmaceuticals, while Lifeward will focus on its medical technology business. Lifeward shares jumped more than 10% after the announcement but remain down around 65% year-to-date; completion of the transaction is still subject to customary conditions. » Więcej na de.investing.com


  • Oramed receives $18 million from Scilex and announces cash dividend

    Oramed has received a payment of $18 million from Scilex, fulfilling all obligations under an option agreement and raising the total return on the original $99.5 million investment to $118 million. Oramed also retains a $27 million promissory note, a $12 million convertible note (conversion price $36 per share), warrants and a nine‑year royalty/license interest in Scilex products. The board approved a cash dividend of $0.25 per share (ex‑date January 16, 2026; payment January 26, 2026), to be financed from surplus funds; the share price then rose by about 6.2%. » Więcej na de.investing.com


  • Oramed Pharmaceuticals: Leonard Sank steps down from director post after 18 years

    Leonard Sank has announced he will resign his mandate on the supervisory board of Oramed Pharmaceuticals effective January 1, 2026. The company emphasizes that his resignation is not due to disagreements over management, policies, or practices. Sank served 18 years as a director. » Więcej na de.investing.com


  • Oramed completes repurchase of Scilex warrants for $28.5m

    Oramed received a total of $28.5 million from Scilex for the repurchase of warrants to acquire 6,500,000 Scilex common shares (two tranches: 3,370,000 shares for $14 million and 3,130,000 shares for $13 million, plus $1.5 million in option fees). The warrants had an exercise price of $0.01 and were repurchased under an agreement disclosed in July. In addition, Oramed repurchased 1,155,367 of its own common shares for about $2.58 million and ended a joint venture with HTIT/Technowl; the company now plans to continue its oral insulin program independently and to initiate a new U.S. study. » Więcej na de.investing.com


  • Oramed buys back HTIT shares and ends joint venture

    Oramed repurchased 1,155,367 common shares of Hefei Tianhui Biotech (HTIT) at $2.23 each (about $2.58 million) and had the shares cancelled. The company terminated the joint-venture agreement with HTIT and Technowl after HTIT failed to meet closing conditions. Oramed released preliminary, unaudited financials as of September 30, 2025, and launched a new U.S. study for its oral insulin program with 60 identified high responders. It also completed the first tranche of an option repurchase agreement with Scilex (3,130,000 shares for $13 million) and increased the number of authorized shares under its stock option plan by 2,000,000 to 9,500,000. » Więcej na de.investing.com

W 2026 roku Oramed Pharmaceuticals wypłaciła już 0,21 € dywidend. Ostatnia wypłata nastąpiła w styczeń.

Dane finansowe

W ostatnim kwartale Oramed Pharmaceuticals osiągnęła przychody w wysokości 0 € i zysk netto w wysokości 16,25 mln €

(EUR) wrzesień 2026
YoY
Przychody 0 -
Zysk brutto 0 100,00%
Zysk netto 16,25 mln 60,59%
EBITDA 24,99 mln 50,69%

Dane fundamentalne

Wskaźnik Wartość
Kapitalizacja rynkowa
141,48 mln €
Liczba akcji
43,49 mln
Maksimum/minimum z 52 tygodni
4,99 € - 2,30 €
Stopa dywidendy
6,00%
Dywidendy TTM
0,21 €
Beta
1,28
C/Z (PE Ratio)
1,02
PEG (PEG Ratio)
0,00
C/WK (PB Ratio)
0,44
C/S (PS Ratio)
0,00

Profil spółki

Oramed Pharmaceuticals Inc. prowadzi badania i rozwój farmaceutycznych rozwiązań do leczenia cukrzycy oraz wykorzystania doustnych kapsułek lub tabletek do podawania polipeptydów. Jego zastrzeżonym produktem flagowym jest ORMD-0801, doustna kapsułka z insuliną, która zakończyła badania kliniczne fazy II w leczeniu osób chorych na cukrzycę. Spółka rozwija także ORMD-0901, doustną kapsułkę z peptydem glukagonopodobnym-1, która zakończyła badania kliniczne fazy I w leczeniu cukrzycy typu 2; a także terapię odchudzającą w postaci doustnej kapsułki z leptyną. Spółka wcześniej funkcjonowała pod nazwą Integrated Security Technologies, Inc. i zmieniła nazwę na Oramed Pharmaceuticals Inc. w kwietniu 2006 roku. Oramed Pharmaceuticals Inc. została założona w 2002 roku i ma siedzibę w Nowym Jorku (Nowy Jork).

Nazwa
Oramed Pharmaceuticals
CEO
Nadav Kidron
Siedziba New York City, ny
Stany Zjednoczone
Strona internetowa
Sektor
Materiały podstawowe
Branża
Chemikalia
Debiut giełdowy
01.05.2007
Pracownicy 13

Symbole giełdowe

Giełda Symbol
Tlv
ORMP.TA
NASDAQ
ORMP
Frankfurt
OJU1.F
Düsseldorf
OJU1.DU
München
OJU1.MU
🍪

Parqet  używa plików cookie. Dowiedz się więcej